People on HCV treatment

This indicator measures progress of treatment coverage among people living with viraemic HCV, towards the 2030 hepatitis elimination goals.

Number of people diagnosed with chronic hepatitis C infection who have initiated HCV curative treatment during the reporting year and cumulatively since 2015.

By country and WHO region

Country-reported data: The indicator is compiled from routine national programme, surveillance, drug supply management systems, clinical or health information system records.

Data should cover the reporting year and the geographical and population scope reported by the country. Countries should describe whether the data are national or subnational, which sectors and facilities are included, and whether individual-level deduplication or record linkage is used.

Modelled estimates: Where complete country-reported data are unavailable, WHO may produce a country-calibrated estimate using available programme data, epidemiological evidence, demographic data and other relevant inputs. The modelled estimate is intended to provide a coherent value for the specified reference year and may not equal a value reported directly by the country.

HCV model structure: the HCV model employs a Markov/semi-dynamic natural history framework that follows people with viraemic infection across stages of liver disease, by age and sex, over time using disease progression and mortality (all-cause and liver-related) rates. It incorporates inputs from demographic profiles, HCV diagnosis and treatment initiation schedules, and subsequent cure (sustained virological response, SVR).

Regional estimates are calculated as the sum of country level data in each of the WHO regions.

Number

Every two years

Continuous at country level reported every two years to WHO

Comparability and Interpretation:Differences between countries may reflect reporting practices and programme maturity rather than differences in access to treatment alone. Annual and cumulative treatment indicators should be interpreted separately.

This dataset contains a combination of country-reported data and WHO-supported modelled estimates. Values may differ because they are derived from different data sources, population coverage, reference years and methodologies. Country-reported data are intended primarily for national programme monitoring, whereas modelled estimates are intended to support standardized comparisons across countries and over time. Direct comparisons between country-reported and modelled values, or between countries represented by different observation types, should therefore be made with caution. Differences between WHO estimates and official national figures should not necessarily be interpreted as errors but may reflect methodological and data-source differences

hepatitisreporting@who.int

Diana Faini

3528

Variability in national reporting systems, treatment monitoring platforms and patient tracking mechanisms may affect completeness and accuracy. Cumulative treatment figures may include individuals with reinfection or retreatment depending on national reporting procedures.